https://scholars.lib.ntu.edu.tw/handle/123456789/568726
標題: | Generation and Characterization of DNA Vaccines Targeting the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus | 作者: | Kim T.W. Lee J.H. Hung C.-F. Peng S. Roden R. Wang M.-C. Viscidi R. Tsai Y.-C. He L. PEI-JER CHEN Boyd D.A.K. Wu T.-C. |
公開日期: | 2004 | 出版社: | American Society for Microbiology | 卷: | 78 | 期: | 9 | 起(迄)頁: | 4638-4645 | 來源出版物: | Journal of Virology | 摘要: | Severe acute respiratory syndrome (SARS) is a serious threat to public health and the economy on a global scale. The SARS coronavirus (SARS-CoV) has been identified as the etiological agent for SARS. Thus, vaccination against SARS-CoV may represent an effective approach to controlling SARS. DNA vaccines are an attractive approach for SARS vaccine development, as they offer many advantages over conventional vaccines, including stability, simplicity, and safety. Our investigators have previously shown that DNA vaccination with antigen linked to calreticulin (CRT) dramatically enhances major histocompatibility complex class I presentation of linked antigen to CD8 + T cells. In this study, we have employed this CRT-based enhancement strategy to create effective DNA vaccines using SARS-CoV nucleocapsid (N) protein as a target antigen. Vaccination with naked CRT/N DNA generated the most potent N-specific humoral and T-cell-mediated immune responses in vaccinated C57BL/6 mice among all of the DNA constructs tested. Furthermore, mice vaccinated with CRT/N DNA were capable of significantly reducing the titer of challenging vaccinia virus expressing the N protein of the SARS virus. These results show that a DNA vaccine encoding CRT linked to a SARS-CoV antigen is capable of generating strong N-specific humoral and cellular immunity and may potentially be useful for control of infection with SARS-CoV. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84984586321&doi=10.1128%2fJVI.78.9.4638-4645.2004&partnerID=40&md5=4f39652ca20fa5b51e155b9118ad2baf https://scholars.lib.ntu.edu.tw/handle/123456789/568726 |
ISSN: | 0022-538X | DOI: | 10.1128/JVI.78.9.4638-4645.2004 | SDG/關鍵字: | calreticulin; CD8 antigen; DNA vaccine; major histocompatibility antigen class 1; nucleocapsid protein; SARS coronavirus antigen; unclassified drug; virus antigen; animal experiment; animal model; article; cellular immunity; controlled study; drug effect; drug efficacy; drug potency; female; humoral immunity; immunogenicity; infection control; mouse; mouse strain; nonhuman; priority journal; SARS coronavirus; severe acute respiratory syndrome; T lymphocyte; vaccination; Vaccinia virus; virus titration |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。